BY Special Report

• Research co-funded by EZZ suggests that three healthy ageing compounds – including NMN – work well in combination
• University of Auckland research published in the peer-reviewed journal Redox Biology
• EZZ pursuing research partnerships with academia to develop health and wellness products backed by scientific validation

Special Report: Co-funded by EZZ Life Science, University of Auckland research proposes that three compounds associated with healthy ageing may act more effectively in combination.

Published in the peer-reviewed journal Redox Biology, the research report examines nicotinamide mononucleotide/nicotinamide riboside (NMN/NR), pyrroloquinoline quinone (PQQ), and ergothioneine (EGT).

The paper suggests each targets different aspects of mitochondrial decline, the age-related process by which the cell’s energy-producing structures deteriorate.

NMN/NR is thought to boost levels of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy production and repair processes.

PQQ promotes the growth of new mitochondria, which produce chemical energy.

EGT acts as a targeted antioxidant, neutralising harmful free radicals inside mitochondria.

The researchers propose the three compounds form a complementary loop, though they acknowledge direct human trial evidence for the combination remains limited.

“Existing preclinical and preliminary clinical evidence indicates that these three compounds possess potential protective effects across cardiovascular, neurological, metabolic, musculoskeletal, immune, skin and reproductive systems,” the paper says.

“Nevertheless, systematic research is still needed to optimise dosages, develop combination strategies, and refine delivery systems.”

The report says future studies should focus on multi-target mechanism validation, long-term safety assessments and the use of precision biomarkers “to advance this tri-axial strategy toward clinical translation”.

The research was funded by EZZ Life Science (ASX: EZZ), the Royal Society of New Zealand Catalyst Seeding Fund, Health and Happiness HK and Oxyenergy.

 

Longevity a focus area for EZZ
Healthy ageing is a key focus for EZZ, a genomic life science company with several NMN-based products.

In September 2025, the US Food and Drug Administration (FDA) confirmed NMN as lawful for use in dietary supplements.

Australia’s Therapeutic Goods Administration (TGA) followed suit in December 2025, adding NMN to its list of permissible ingredients for listed complementary medicines.

“Our focus at EZZ was on NMN and the research summary said the three compounds had potentially extensive protective effects,” EZZ Chief Strategy Officer Glenn Cross said.

“We were one of the first companies to come out with an NMN product. ”

“Further research is still needed, but this study may lead to longer term validation and safety assessments.”

EZZ sells NMN products through Southeast Asia and New Zealand and is allowed to sell in most European countries, the US and Australia.

 

Growing interest in healthy aging
The research notes the rapidly ageing population has intensified interest in understanding the ageing process and making people healthier for longer.

“Ageing demographics impose substantial socioeconomic challenges on healthcare systems and societal structures worldwide,” the report says.

Ageing, of course, is linked with a range of chronic diseases.

These include heart failure, dementia, strokes, most cancers, diabetes and metabolic disorders, chronic lung disease and vision loss.

 

Backed by evidence
Cross said EZZ was committed to pursuing research partnerships with academic institutions, to develop health and wellness products backed by scientific validation.

The company has a research services deal with the University of Sydney. This explores the bone health benefits of an EZZ proprietary formulation containing lysine, calcium carbonate, vitamin D3, vitamin B2, zinc gluconate, taurine, glutamine, glycine and magnesium.

Results of the research, which started in mid-2025, are expected in March 2027.

“Where possible, EZZ bases its anti-aging products on research and backs them with solid scientific evidence,” Cross said.

He said few other companies in the sector did so.

“It’s about EZZ working to differentiate itself from other wellness and nutraceuticals businesses.”